Who
Kathryn C. Zoon
Director
Company insider
Files Form 4 as: Director, Emergent BioSolutions.
In numbers
- Trades disclosed
- 44
- Buys
- 0
- Sells
- 23
- Bought
- $0
- Sold
- $2.3M
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 8 Nov 2016
- Last trade
- 1 May 2026
- Last filed
- 4 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 May 2026filed 4 May 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Sold | $135K16,145 at $8.36 | filing |
| 1 May 2026filed 4 May 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Sold | $9,4811,057 at $8.97 | filing |
| 1 May 2026filed 4 May 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Sold | $135K16,145 at $8.36 | filing |
| 1 May 2026filed 4 May 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Sold | $9,4811,057 at $8.97 | filing |
| 30 Apr 2026filed 4 May 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code A | —25,344 at $0.00 | filing |
| 30 Apr 2026filed 4 May 2026 | EBS Emergent BioSolutionsoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,296 at $0.00 | filing |
| 30 Apr 2026filed 4 May 2026 | EBS Emergent BioSolutionsoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,296 at $0.00 | filing |
| 30 Apr 2026filed 4 May 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code A | —25,344 at $0.00 | filing |
| 15 Aug 2025filed 18 Aug 2025 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Sold | $63K7,086 at $8.87 | filing |
| 30 Apr 2025filed 2 May 2025 | EBS Emergent BioSolutionsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,824 at $0.00 | filing |
| 30 Apr 2025filed 2 May 2025 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code A | —34,403 at $0.00 | filing |
| 12 Mar 2025filed 12 Mar 2025 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Sold | $57K10,000 at $5.73 | filing |
| 4 Jun 2024filed 6 Jun 2024 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Sold | $61K10,000 at $6.11 | filing |
| 29 May 2024filed 31 May 2024 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Sold | $8,4361,830 at $4.61 | filing |
| 23 May 2024filed 28 May 2024 | EBS Emergent BioSolutionsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,748 at $0.00 | filing |
| 23 May 2024filed 28 May 2024 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code A | —17,430 at $0.00 | filing |
| 21 May 2024filed 23 May 2024 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Sold | $6,2941,089 at $5.78 | filing |
| 2 Jun 2023filed 24 Jul 2023 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Sold | $15K1,830 at $8.35 | filing |
| 25 May 2023filed 24 Jul 2023 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Sold | $14K1,700 at $8.38 | filing |
| 25 May 2023filed 30 May 2023 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code A | —33,847 at $0.00 | filing |
News
Comparing Monte Rosa Therapeutics (NASDAQ:GLUE) and Emergent Biosolutions (NYSE:EBS)EBS · tickerreport.com · 16 Oct 2026
0 headlines in the last 90 days name Kathryn C. Zoon; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.